Strength of patient cohorts and biobanks for cardiomyopathy research by 
 
 
 University of Groningen






IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2020
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
DOSIS consortium (2020). Strength of patient cohorts and biobanks for cardiomyopathy research.
Netherlands Heart Journal, 28(Suppl 1), S50-S56. https://doi.org/10.1007/s12471-020-01456-4
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 26-12-2020
Review Article
Neth Heart J (2020) 28 (Suppl 1):S50–S56
https://doi.org/10.1007/s12471-020-01456-4
Strength of patient cohorts and biobanks for
cardiomyopathy research
R. A. de Boer · L. L. A. M. Nijenkamp · H. H. W. Silljé · T. R. Eijgenraam · R. Parbhudayal · B. van Driel · R. Huurman ·
M. Michels · J. Pei · M. Harakalova · F. H. M. van Lint · M. Jansen · A. F. Baas · F. W. Asselbergs · J. P. van Tintelen ·
B. J. J. M. Brundel · L. M. Dorsch · M. Schuldt · D. W. D. Kuster · J. van der Velden for DOSIS consortium
© The Author(s) 2020
Abstract In 2011 the Netherlands Heart Foundation
allocated funding (CVON, Cardiovasculair Onderzoek
Nederland) to stimulate collaboration between clin-
ical and preclinical researchers on specific areas of
research. One of those areas involves genetic heart
diseases, which are frequently caused by pathogenic
variants in genes that encode sarcomere proteins. In
2014, the DOSIS (Determinants of susceptibility in in-
herited cardiomyopathy: towards novel therapeutic
approaches) consortium was initiated, focusing their
research on secondary disease hits involved in the on-
set and progression of cardiomyopathies. Here we
highlight several recent observations from our con-
sortium and collaborators which may ultimately be
relevant for clinical practice.
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Introduction
Inherited cardiomyopathies, caused by pathogenic
variants in genes encoding proteins that regulate car-
diomyocyte contractility, are a major cause of morbid-
ity and mortality. In 50–60% of familial hypertrophic
cardiomyopathy (HCM) and 30–40% of dilated car-
diomyopathy (DCM), a pathogenic gene variant can
be identified. The most common genes that are af-
fected in HCM are MYH7,MYBPC3 and TNNT2,which
encode the thick filament proteins myosin heavy
chain, cardiac myosin-binding protein-C (cMyBP-
C), and the thin filament protein troponin T. In DCM
the titin (TTN) gene, which encodes the giant myofila-
ment protein titin, is themost frequently affected gene
(~15–20% of all gene variants) [1]; in particular gene
variants that lead to TTN truncation have been shown
to be pathogenic [2]. In addition, in the Netherlands,
a founder mutation in the PLN gene, which encodes
the calcium-handling protein phospholamban, was
Dutch contribution to the field
 DOSIS represents a national research consor-
tium on cardiomyopathies.
 DOSIS researchers have shownmore severe dias-
tolic dysfunction in female than male HCM pa-
tients at the time of surgery.
 Indexation for body size is needed to set the di-
agnostic threshold for left ventricular thickening
in HCM.
 Cell-to-cell variability is present in the hearts of
patients with a Dutch founder mutation.
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Fig. 1 Activation of a cardiomyocyte triggers calcium entry
and release of calcium from the sarcomplasmic reticulum (SR),
which results in contraction of the cardiac myofibrils. To relax
the cardiomyocyte, calcium is pumped back into the SR, and
out of the cell via the sodium-calcium exchanger (NCX). My-
ofibrils consist of sarcomeres composed of the thin actin and
thick myosin filament, and the third filament titin. Sarcomeres
consist of sub-regions (depicted by the different bands), which
underlie the striated pattern of cardiac muscle. Gene variants
that cause cardiomyopathies are frequently found in myosin
heavy chain, troponin T, cardiac myosin-binding protein-C (lo-
cated in the Z-zone) and titin. (Figure is adapted from Sequeira
at al. [34])
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Fig. 2 Disease modi-
fiers in inherited cardiomy-
opathies (PQC protein qual-
ity control)
identified in 2012 as a now well-known cause of DCM
and arrhythmogenic cardiomyopathy [3, 4]. Fig. 1
depicts a cardiomyocyte to illustrate the affected pro-
teins involved in cardiomyopathies. Upon activation
of a cardiomyocyte, calcium enters the cell via the
L-type calcium channel, which subsequently releases
calcium from the intracellular calcium store, the sar-
coplasmic reticulum. Calcium binds to the troponin
complex, which induces a conformational change of
troponin-tropomyosin, and thereby releases binding
sites for myosin heads on the thin actin filament.
Binding of myosin to actin (so-called cross-bridge)
results in force development. The kinetics of cross-
bridge cycling is regulated by cMyBP-C, and the giant
protein titin, encoded by TTN and linked with DCM,
underlies passive stiffness of sarcomeres [5].
In past years the number of genes in genetic diag-
nostic panels has increased with the hope to identify
a disease-causing variant in a larger group of patients
and their family members. However, recent stud-
ies conclude that the additional benefit of screening
large numbers of genes is disappointingly low and of
marginal clinical utility [6, 7]. Numerous new TTN
gene variants have been identified, mainly because of
its large size. A study in three European cardiogenic
centres showed that missense and non-frameshifting
insertions/deletions variants are most likely benign,
as reference populations showed comparable fre-
quencies of these rare TTN variants [8]. The current
panels thus rather increase the number of variants
with unknown significance, which are likely benign,
though they may have a modifier role in disease.
Cardiomyopathy patients with a suspected genetic
aetiology should be referred for genetic screening.
For HCM this includes patients with asymmetric left
ventricular hypertrophy, not explained by abnormal
loading conditions, with or without a clear family
history. For DCM this includes patients with non-
ischaemic DCM, not fully explained by other aetio-
logical factors. Young age of onset and familial oc-
currence are important parameters that hint towards
a genetic aetiology. However, late onset in seem-
ingly sporadic cases does not exclude a genetic origin
due to the reduced penetrance and variable disease
expression. All HCM and DCM patients in whom
genetic screening was performed can be added to
the biobanks, including their relatives (asymptomatic
mutation carriers).
Since cardiomyopathies continue to constitute one
of the most common causes of sudden cardiac death
in the young and still represent major causes for
cardiac transplantation, adequate identification of
additional disease triggers and understanding the
pathomechanisms is of utmost importance. The clin-
ical approach is furthermore complicated since inher-
ited cardiomyopathies are clinically heterogeneous:
age-dependent penetrance and disease-severity differ
greatly between patients with the identical genetic
variant. The mechanisms that underlie the variation
in disease expression are still largely unknown. By
combining cellular, genetic and clinical data from
well-phenotyped national patient cohorts, DOSIS
strived to define disease factors (i.e. secondary hits)
that in addition to the pathogenic gene variant cause
and aggravate cardiac disease in cardiomyopathy pa-
tients (Fig. 2; Tab. 1). Several recent observations are
highlighted below.
Indexation for body size to set the diagnostic
threshold for left ventricular thickening
Using a large collection of myectomy samples from
patients with obstructive HCM, we have shown that
there is a sex-specific difference in diastolic function
at the time of myectomy in HCM patients carry-
ing pathogenic variants in MYH7 and MYBPC3 [9].
Women showed more diastolic dysfunction evident
from significantly higher E/e’ ratios, impaired left
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Table 1 Cohorts of DOSIS
Cohort Participating centres Population Biobank collection Aim
Erasmus HCM observa-
tional cohort
Erasmus MC HCM patients and
gene variant carriers
DNA Identify predictive clinical markers for major cardiac
events
BIO FOr CARe observa-
tional cohort








Identify predictive biomarkers for major cardiac
events





n.a. Determine predictive value of environmental factors







Serum Determine effects of trimetazidine on improving my-
ocardial energy efficiency in the pre-clinical disease
stage
Myectomy cohort Erasmus MC, UMC Utrecht HCM patients un-
dergoing septal
myectomy
DNA, cardiac tissue Collect myocardial tissue for use in etiological studies
ventricular filling patterns, and higher tricuspid re-
gurgitation velocities. Of the female patients, 50%
showed grade III diastolic dysfunction, while the ma-
jority of male patients (56%) had only mild (grade I)
diastolic dysfunction. Correction of maximal septal
thickness and left atrial diameter for body surface
area (BSA) resulted in significantly higher values in
female compared with male patients. Histological
and protein analyses revealed more advanced remod-
elling of the heart in female compared with male
HCM patients evident from higher levels of fibrosis
and activation of the cardiac foetal gene program,
which is characteristic of heart failure. In addition
to genetic screening, the current diagnostic crite-
rion of hypertrophy is a maximal left ventricular wall
thickness of ≥15mm, or ≥13mm in first-degree rela-
tives of HCM patients. As the hearts of women, and
in general relatively small persons, are smaller than
the hearts of men, this threshold for the diagnosis
of HCM should probably be corrected for body size
[10]. The current diagnostic threshold, which does
not take into account body size, may likely explain
the male predominance in HCM patient cohorts,
simply because males in general have larger hearts.
A recent study in a Dutch cohort of 199 genotype-pos-
itive subjects, family members of HCM patients who
were referred for cardiac screening between 1995 and
2018, indexation of wall thickness by BSA decreased
the number of HCM diagnoses [11]. Moreover, pre-
dictive accuracy for HCM-related events (mortality,
cardiac transplantation, implantable cardioverter-
defibrillator implantation and septal reduction ther-
apy) improved significantly after indexation by BSA.
These studies indicate that correcting left ventricular
thickness for body size should be considered for the
diagnosis of HCM and longitudinal follow-up stud-
ies in larger cohorts of preclinical genotype-positive
individuals are needed to confirm this.
Altered metabolism as key driver of disease in
cardiomyopathies
Several studies suggest an important role for sec-
ondary disease modifiers such as additional epi-
genetic and genetic variations and environmental
disease triggers. Compelling data have accumulated
that obesity is an overarching risk factor, also for
age-of-onset and severity of cardiomyopathies. Proof
that obesity contributes to disease onset and severity
comes from cohort studies. The international HCM
Share registry showed that patients with a high body
mass index have a significantly increased risk of heart
failure, more advanced left ventricular outflow tract
obstruction and more arrhythmias (i.e. HCM-related
outcomes) [12]. Moreover, a prospective study in
adolescent men demonstrated that even mildly ele-
vated body weight in late adolescence significantly
increased the risk to develop dilated cardiomyopathy
in adulthood [13]. At the heart level, a recent pro-
teomics study in human HCM tissue samples showed
reduced levels of energy metabolism proteins [14].
This observation is in line with studies in human
HCM showing energy deficiency of the heart [15,
16]. Energy deficiency has been proposed as the pri-
mary variant-induced pathomechanism of HCM [17],
which is supported by studies showing reduced car-
diac efficiency in preclinical asymptomatic carriers of
sarcomere gene variants in the absence of cardiac hy-
pertrophy [16, 18]. Accordingly, DCM caused by TTN
gene variants has been linked with mitochondrial
dysfunction and metabolic perturbations as cause
of disease progression [19]. Overall, these studies
indicate that timely disease stage-specific treatment
of metabolic perturbations may slow down disease
progression in cardiomyopathy patients [20]. An ob-
servational cohort to determine the predictive value
of metabolic biomarkers (BIO FOr CARe: identifica-
tion of biomarkers for development and progression
of HCM in carriers of the Dutch MYBPC3 founder car-
riers) and a clinical trial using metabolic drug therapy
aimed to improve energetics of the heart at preclinical
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Fig. 3 By combining cel-
lular, genetic and clinical
data from well-phenotyped
national patient cohorts,
DOSIS strives to define dis-
ease factors that in addi-
tion to the pathogenic gene
variant cause and aggra-
vate cardiac disease in car-
diomyopathy patients
stage in HCM gene variant carriers are currently being
performed by several DOSIS principal investigators
(ENERGY trial) [21].
Altered protein quality control as disease
modifier in cardiomyopathy
An age-related decline in protein quality control
(PQC) has been proposed as a contributor to dis-
ease progression in cardiomyopathy. As sarcomere
proteins are the most abundant proteins in the heart,
maintenance of sarcomere structure and function de-
pends on PQC mechanisms. Pathogenic gene variants
result in poison polypeptides or reduced protein lev-
els (haploinsufficiency) and may trigger PQC and/or
stress cellular protein homeostasis. DCM patients
with truncating TTN variants show a relatively mild
disease course, though with significant excess mortal-
ity in elderly patients. The latter may be explained by
an age-related deterioration of the PQC mechanisms.
As life expectancy increases, TTN-associated morbid-
ity and mortality will likely become more prevalent
[22]. Also in PLN-associated cardiomyopathy, protein
aggregation and activation of PQC pathways has been
observed in end-stage disease [23].
Terminally misfolded and aggregation-prone pro-
teins are cleared by the two degradation systems,
the ubiquitin-proteasome system and autophagy [24].
Furthermore, pathways of PQC are strongly linked
to cell architecture, such as the microtubules net-
work. DOSIS studies in a large set of cardiac tis-
sues from a well-characterised HCM patient group
showed altered PQC with several specific changes
in gene-variant positive patients (genotype-positive)
compared with genotype-negative patients and non-
failing controls [25]. Heat shock proteins (HSP) in-
volved in protein stabilisation (HSPB1) and refolding
(HSPD1, HSPA2) were increased in genotype-positive
HCM compared with controls. In addition, tubulin
and acetylated-tubulin levels were significantly higher
in HCM compared with controls, especially in HCM
with truncating variants in MYBPC3, which cause
protein haploinsufficiency. cMyBP-C protein levels
were inversely correlated with α-tubulin levels sug-
gesting a compensatory tubulin response to maintain
cardiomyocyte structure, though this may be at the
expense of cardiac function. Our study indicates that
proliferation of the microtubular network represents
a novel pathomechanism in cMyBP-C haploinsuf-
ficiency-mediated HCM. Recent studies in human
heart failure identified a central role for detyrosinated
microtubules in regulating cardiomyocyte function
and demonstrated the functional benefit upon rever-
sal of this modification [26, 27]. This is of clinical
importance since it represents a potential treatment
target to improve cardiac function in HCM.
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Cell-to-cell mRNA/protein variability as
pathomechanism in cardiomyopathy
As familial cardiomyopathies represent an autoso-
mal dominant genetic disorder, most patients are
heterozygous for the mutation and carry one variant
and one normal wild-type allele. In cardiomyopathy
patients, the heart of a genotype-positive individual
produces the variant protein in addition to the normal
protein. As indicated above, the homeostasis of cel-
lular proteins is tightly regulated by the PQC system,
but it is also regulated at the mRNA level by non-sense
mediated mRNA decay. Both systems are needed to
suppress the accumulation of variant protein while
keeping the normal protein at sufficient levels in
cardiac muscle cells. It was recently shown that tran-
scription of both alleles occurs independently and in
a stochastic manner, where one cell favours one allele
and the next cell favours the other allele [28]. This
burst-like, stochastic on/off switching of allele tran-
scription does not affect mRNA and protein levels in
case of homozygous wild-type alleles. However, het-
erozygosity of alleles as present in genotype-positive
individuals may introduce cell-to-cell variation with
one cardiomyocyte expressing high levels of variant
protein, while variant levels may be low in another
cardiomyocyte [29]. Indeed, it has been shown that
MYH7 gene variants cause a variable variant to wild-
type ratio of mRNA expression in cardiomyocytes
from the same heart [28, 30]. The DOSIS consortium
showed intercellular variation of cMyBP-C myofila-
ment protein expression due to truncating MYBPC3
variants in the myocardium of HCM patients [31].
The functional consequences of the variable pro-
tein expression, which results in a mosaic pattern
of cardiomyocytes with low and high variant/wild-
type expression, remain to be determined. Loss of
cMyBP-C causes severe dysfunction in mouse studies
and engineered heart tissue [32, 33]. We propose that
the intercellular variation of cMyBP-C protein levels
causes inhomogeneous contraction and relaxation
and underlies the formation of myofibrillar disar-
ray, a currently unexplained disease characteristic of
HCM. As ageing reduces the quality of PQC, an age-
dependent progression of the degree of allelic im-
balance and cell-to-cell variation may contribute to
cardiomyopathy development.
In conclusion, monogenetic cardiomyopathies
have been intensely studied in the last three decades,
and this has resulted in major progress in under-
standing what genes are involved. On the other hand,
the striking heterogeneity, the highly variable age of
onset, and the presence of gene variant carriers that
never develop disease is as of yet largely unexplained.
Given the profound repercussion for carriers, patients
and family members we must improve our under-
standing of the individual’s response to the presence
of a pathogenic gene variant.
DOSIS aims to study unexplored mechanisms that
will probably modify the pathogenic gene variant
(Fig. 3). We have set up important initiatives and col-
laborations and have generated preliminary results
showing that environmental and genetic modifiers
are indeed important in our understanding. In the
future we will step up our initiatives and projects
and have identified an agenda, which contains—what
we feel—important additional factors that when fully
understood will guide clinicians in proper diagno-
sis, risk prediction, prognostication and, ultimately,
cause-specific novel treatments.
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